ArticleFrontiers in pharmacology2020

The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study.

Hélène Haguet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.